Background/Aim: Quality of life is reduced in people living with leprosy as a result of its impact on human activities. Lipid profile means pattern of lipids in the blood, which is routinely done to assess cardiovascular risk. The aim of this study is to assess the risk of cardiovascular diseases among the leprosy patients settlement at Ossiomo-Ogan, Edo state. Method: Blood samples were collected from a total number of one hundred and eight (108) (57 leprosy patients and 51 controls) subjects. The lipid profiles of the participants were determined using standard methods. Results: Significantly (p < 0.001) higher mean serum levels of total cholesterol, triglycerides, HDL and LDL in leprosy patients compared with the healthy controls were obtained. There is significant positive correlation between artherogenic index and levels of total cholesterol (r = 0.663; p < 0.001); triglyceride (r = 0.901; p < 0.001); HDL (r = 0.284; p = 0.003); and LDL (r = 0.626; p < 0.001) in leprosy patients. However, all the control subjects and 54 (94.7%) of the leprosy patients had low cardiovascular disease risk, while 3 (2.8%) indicated moderate CVD risk. None of the participants had high risk of developing cardiovascular disease. Conclusion: In this study, lipid profile levels of leprosy patients significantly increased despite moderate level of BMI. This study also showed significant positive correlation between the anthrogenic index of plasma and all the lipid profile. Many of the leprosy patients are not conscious of their diet which was tilted towards heavy carbohydrate and fatty meals. None of the participants is at high risk of cardiovascular diseases but the risk may increase with further elevation of the lipid profiles. Efforts should be made by all stakeholders to improve on the awareness of leprosy disease and encourage the sufferers to live decent lives.
References
[1]
World Health Organization (2017) Guide Lines for the Diagnosis, Treatment and Prevention of Leprosy. www.who.int
[2]
Wangara, F., Kipruto, H., Ngesa, O., Kayima, J., Masini, E., Sitienei, J. and Ngari, F. (2019) The Spatial Epidemiology of Leprosy in Kenya: A Retrospective Study. PLoS Neglected Tropical Diseases, 13, e0007329.
https://doi.org/10.1371/journal.pntd.0007329
[3]
WHO (2015) Global Leprosy Update, 2014: Need for Early Case Detection. Weekly Epidemiological Record, WER No. 36, 461-474.
https://www.who.int/publications/i/item/who-wer9036
[4]
World Health Organization (2017) Leprosy Fact Sheet. www.searo.who.int
[5]
World Health Organization (2018) Global Leprosy Update, 2017: Reducing the Disease Burden Due to Leprosy. The Weekly Epidemiological Record, 93, 445-456.
[6]
World Health Organization (2017) Global Leprosy Update: Accelerating Reduction of Disease Burden. The Weekly Epidemiological Record, 92, 501-519.
[7]
Muhammad, F., Abdulkareem, J.H. and Chowdhury, A.B.M. (2017) Major Public Health Problems in Nigeria: A Review. South East Asia Journal of Public Health, 7, 6-11.
[8]
Nigeria Centre for Disease Control Leprosy (2017). www.ncdc.gov.ng
[9]
Gupta, A., Koranne, R.V. and Kaul, N. (2002) Study of Serum Lipids in Leprosy. Indian Journal of Dermatology, Venereology and Leprology, 68, 262-266.
[10]
Bhatnagar, P., Wickramasinghe, K., Williams, J., Rayner, M. and Townsend, N. (2015) The Epidemiology of Cardiovascular Disease in the UK. Heart, 101, 1182-1189. https://doi.org/10.1136/heartjnl-2015-307516
[11]
Rafieian-Kopaei, M., Setorki, M., Doudi, M., Baradaran, A. and Nasri, H. (2014) Atherosclerosis: Process, Indicators, Riskfactors and New Hopes. International Journal of Preventive Medicine, 5, 927-946.
[12]
Silva, R.V.G., de Araújo, R.S., Aarao, T.L.S., da Silva Costa, P.D., Sousa, J.R. and Quaresma, J.A.S. (2017) Correlation between Therapy and Lipid Profile of Leprosy Patients: Is There a Higher Risk for Developing Cardiovascular Diseases after Treatment? Infectious Diseases of Poverty, 6, Article No. 82.
https://doi.org/10.1186/s40249-017-0295-1
[13]
De Rosa, S., Arcidiacono, B., Chiefari, E., Brunetti, A., Indolfi, C. and Foti, D.P. (2018) Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links. Frontiers in Endocrinology, 9, Artice No. 2.
https://doi.org/10.3389/fendo.2018.00002
[14]
Charan, J. and Biswas, T. (2013) How to Calculate Sample Size for Different Study Designs in Medical Research. Indian Journal of Psychological Medicine, 35, 121-126. https://doi.org/10.4103/0253-7176.116232
[15]
Bassey, I.E., Inyang, I.E., Akpan, U.O., Isong, I.K.P., Icha, B.E. and Ayawan, V.M. (2020) Cardiovascular Disease Risk Factors and Markers of Oxidative Stress and DNA Damage in Leprosy Patients in Southern Nigeria. PLoS Neglected Tropical Diseases, 14, e0008749. https://doi.org/10.1371/journal.pntd.0008749
[16]
Friedewald, W.T., Levy, R.I. and Fredrickson, D.S. (1972) Estimation of the Concentration of Low Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge. Clinical Chemistry, 18, 499-502.
https://doi.org/10.1093/clinchem/18.6.499
[17]
Dobiásová, M. (2006) AIP—Atherogenic Index of Plasma as a Significant Predictor of Cardiovascular Risk: From Research to Practice. Vnitrni Lekarstvi, 52, 64-71.
[18]
Banach, M., Jankowski, P., Józwiak, J., et al. (2016) PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science, 13, 1-45.
[19]
Langlois, M.R., Chapman, M.J., Cobbaert, C., the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative (2018) Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clinical Chemistry, 4, 1006-1033. https://doi.org/10.1373/clinchem.2018.287037
[20]
Langlois, M.R., Nordestgaard, B.G., Langsted, A.D., the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative (2019) Quantifying Atherogenic Lipoproteins for Lipid-Lowering Strategies: Consensus-Based Recommendations from EAS and EFLM. Atherosclerosis, 294, 46-61.
[21]
Brennan, P.J. (2015) 50 Years on: The United States-Japan Cooperative Medical Science Program 1965-2015; Part II, the Leprosy Joint Panel. Japanese Journal of Leprosy, 84, 79-86.
[22]
Reibel, F., Cambau, E. and Aubry, A. (2015) Update on the Epidemiology, Diagnosis, and Treatment of Leprosy. Médecine et Maladies Infectieuses, 45, 383-393.
https://doi.org/10.1016/j.medmal.2015.09.002
[23]
Montenegro, R.M.N., Del Carmen Molina, M., Moreira, M. and Zandonade, E. (2011) The Nutritional and Dieting Profiles of Patients Diagnosed with Leprosy Treated in the Primary Healthcare Units of Greater Vitoria, State of Espirito Santo, Brazil. Revista da Sociedade Brasileira de Medicina Tropical, 44, 228-231.
https://doi.org/10.1590/S0037-86822011005000016
[24]
Salgado, C.G., Barreto, J.G., da Silva, M.B., Frade, M.A. and Spencer, J.S. (2016) What Do We Actually Know about Leprosy Worldwide? The Lancet Infectious Diseases, 16, 778. https://doi.org/10.1016/S1473-3099(16)30090-1
[25]
White, C. and Franco-Paredes, C. (2015) Leprosy in the 21st Century. Clinical Microbiology Reviews, 28, 80-94.
[26]
Nwosu, C.M. and Nwosu, S.N.N. (2001) Abnormalities in Serum Lipids and Liver Function in Nigeria Patients with Leprosy. Journal of Medical Investigation and Practice, 2, 5-10.
[27]
Lemes, R.M.R., Silva, C., Marques, M., Atella, G.C., Nery, J., Nogueira, M.R.S., et al. (2020) Altered Composition and Functional Profile of High-Density Lipoprotein in Leprosy Patients. PLoS Neglected Tropical Diseases, 14, e0008138.
https://doi.org/10.1371/journal.pntd.0008138
[28]
Sheikh, G.S., Zubari, N.A., Sheikh, M.H. and Abro, M.R. (2012) Evaluation of Lipid Profile in Leprosy Patients. Medical Forum Monthly, 23, 48-50.
[29]
Nega, T. (2016) Immunological and Lipid Profile among Leprosy Patients at ALERT Centre, Addis Ababa Ethiopia. Master’s Thesis, Addis Ababa University, Addis Ababa.
[30]
Ghulam, S., Viqar, S., Ali, G. and Jehan, A. (2016) Comparative Study of Lipid Profile in Multibacillaryand Paucibacillary Leprosy Patients. Journal of Bahria University Medical and Dental College, 6, 43-46.
[31]
Eichelmann, K., González González, S.E., Salas-Alanis, J.C. and Ocampo-Candiani, J. (2013) Leprosy. An Update: Definition, Pathogenesis, Classification, Diagnosis, and Treatment. Actas Dermo-Sifiliográficas, 104, 554-563.
https://doi.org/10.1016/j.adengl.2012.03.028
[32]
Kumar, N., Saraswai, P.K. and Shanker, A. (1988) Estimation of High Density Lipoprotein Cholesterol in the Diagnosis of Lepromatous Leprosy. Indian Journal of Leprosy, 60, 600-603.
[33]
Moschella, S.L. (2004) An Update on the Diagnosis and Treatment of Leprosy. Journal of the American Academy of Dermatology, 51, 417-426.
https://doi.org/10.1016/j.jaad.2003.11.072
[34]
Hariprasad, C., Rao, A.V., Rao, P.S. and Jan, S.S. (1970) Serum Beta Lipoprotein Levels in Leprosy. International Journal of Leprosy and Other Mycobacterial Diseases, 39, 896-897
[35]
Bansal, S.N., Join, V.K., Dayal, S. and Nagpal, R.K. (1997) Serum Lipid Profile in Leprosy. Indian Journal of Dermatology, Venereology and Leprology, 63, 78-81.
[36]
Davidson, M.H. and Pullipati, V.P. (2021) Dyslipidemia. MSD Manual.
https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/lipid-disorders/dyslipidemia
[37]
Ahaley, S.K., Sardeshmukh, A.S., Suryakar, A.N., et al. (1992) Correlation of Serum Lipids and Lipoproteins in Leprosy. Indian Journal of Leprosy, 64, 91-98.
[38]
Gupta, R.K. and Gupta, S. (1976) Serum Cholesterol and Lipoproteins in Leprosy. The Indian Medical Gazette, 408-410.
[39]
Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., et al. (2004) Effect of Potentially Modifiable Risk Factors Associated with MI in 52 Countries (the INTERHEART Study): Case-Control Study. The Lancet, 364, 937-952.
https://doi.org/10.1016/S0140-6736(04)17018-9
[40]
Zhu, X., Yu, L., Zhou, H., Ma, Q., Zhou, X., Lei, T., Hu, J., Xu, W., Yi, N. and Lei, S. (2018) Atherogenic Index of Plasma Is a Novel and Better Biomarker Associated with Obesity: A Population-Based Cross-Sectional Study in China. Lipids in Health and Disease, 17, Article No. 37. https://doi.org/10.1186/s12944-018-0686-8
[41]
Niroumand, S., Khajedaluee, M., Khadem-Rezaiyan, M., et al. (2015) Atherogenic Index of Plasma (AIP): A Marker of Cardiovascular Disease. Medical Journal of the Islamic Republic of Iran, 29, 240.
